小児急性脳症診療ガイドライン　2023

出版社： 診断と治療社
著者：
発行日： 2023-01-01
分野： 臨床医学：内科  >  小児科学一般
ISBN： 9784787825667
電子書籍版： 2023-01-01 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

3,630 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,630 円(税込)

購入する

商品紹介

6年ぶりとなる今回の改訂では，概念・疫学から診断・検査，管理・治療など，教科書としても使える急性脳症の総論・各論部分はMinds 2007に準拠した2016年版の内容をアップデートし，さらにMinds 2020に基づくシステマティックレビューから推奨文を作成したCQを新たに1つ追加．現時点での“日本の小児急性脳症研究の最大公約数的な到達点”として，小児急性脳症の診療にかかわるすべて医師，必携の書．

目次

  • 小児急性脳症診療ガイドライン2023の概要
    急性脳症の診療フローチャートと本ガイドラインの使い方
    小児急性脳症診療ガイドライン2023 作成組織
    推奨度および推奨グレード一覧
    略語一覧

    第1章クリニカルクエスチョン
    CQ1　体温管理療法（脳平温療法：目標体温36℃）を実施可能な施設において，
    　　　急性脳症を疑う患児に対する本療法の実施はAESDへの進展，後遺症，重篤な
    　　　有害事象を考慮した場合有用か？

    第2章急性脳症の概念と疫学
    1 急性脳症の定義
    2 急性脳症の疫学
    3 急性脳症の予後

    第3章急性脳症の診断と検査
    1 急性脳症の診断に必要な診察と検査，タイミング
    2 急性脳症の鑑別診断
    3 急性脳症の画像診断
    4 急性脳症の脳波検査

    第4章全身管理と体温管理療法（脳低温・平温療法）
    1 けいれん性てんかん重積・けいれん性てんかん遷延状態への対応
    2 急性脳症の全身管理
    3 急性脳症全般に対する体温管理療法
    （脳低温療法：目標体温32～35℃，脳平温療法：目標体温36℃）

    第5章代謝異常による急性脳症
    1 先天代謝異常症による急性脳症の特徴
    2 先天代謝異常症の診断と検査
    3 ミトコンドリア救済の治療

    第6章全身性炎症反応による急性脳症
    1 炎症のマーカー
    2 副腎皮質ステロイドの意義，適応，方法
    3 ガンマグロブリンと血液浄化の意義，適応，方法
    4 急性壊死性脳症（ANE）の診断と治療

    第7章けいれん重積を伴う急性脳症
    1 けいれん重積型（二相性）急性脳症（AESD）の診断と治療
    2 難治頻回部分発作重積型急性脳炎（AERRPS）の診断と治療

    第8章その他の急性脳症
    1 Dravet症候群に合併した脳症の診断と治療
    2 先天性副腎皮質過形成に伴う脳症の診断と治療
    3 可逆性脳梁膨大部病変を有する軽症脳炎・脳症（MERS）の診断と治療
    4 腸管出血性大腸菌（EHEC）感染症に併発する脳症の診断と治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 クリニカルクエスチョン

P.5 掲載の参考文献
1) Nishiyama M, Tanaka T, Fujita K, et al. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
2) Murata S, Kashiwagi M, Tanabe T, et al. Targeted temperature management for acute encephalopathy in a Japanese secondary emergency medical care hospital. Brain Dev 2016 ; 38 : 317-23.
 

第2章 急性脳症の概念と疫学

P.10 掲載の参考文献
1) Behrouz R, Godoy DA, Azarpazhooh MR, et al. Altered mental status in the neurocritical care unit. J Crit Care 2015 ; 30 : 1272-7.
PubMed
2) Slooter AJC, Otte WM, Devlin JW, et al. Updated nomenclature of delirium and acute encephalopathy : statement of ten Societies. Intensive Care Med 2020 ; 46 : 1020-2.
PubMed
3) Mizuguchi M, Yamanouchi H, Ichiyama T, et al. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 : 45-56.
PubMed
a) 厚生科学研究費補助金 (新興・再興感染症研究事業) 研究「インフルエンザの臨床経過中に発生する脳炎・脳症の疫学及び病態に関する研究」班. 平成12年度研究成果報告書. 2001.
 
b) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
4) 森島恒雄, 岡部信彦, 中村祐輔, ら. 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 小児科臨床 2009 ; 62 : 2483-528.
 
5) Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004 ; 63 : 1854-8.
PubMed
6) Sakuma H. Acute encephalitis with refractory, repetitive partial seizures. Brain Dev 2009 ; 31 : 510-4.
PubMed
7) 伊藤泰広, 中井紀嘉, 近藤直英. RPLS/PRES. 別冊 新領域別症候群シリーズ No.26 : 神経症候群 (第2版) (I) -その他の神経疾患を含めて-. 大阪 : 日本臨牀社, 2013 : 283-8.
 
8) 早川文雄. 急性脳症のABC分類. 小児科診療 2011 ; 74 : 937-44.
Medical*Online
P.13 掲載の参考文献
1) Ishikawa T, Asano Y, Morishima T, et al. Epidemiology of acute childhood encephalitis. Aichi Prefecture, Japan, 1984-90. Brain Dev 1993 ; 15 : 192-7.
PubMed
2) Goto S, Nosaka N, Yorifuji T, et al. Epidemiology of pediatric acute encephalitis/encephalopathy in Japan. Acta Med Okayama 2018 ; 72 : 351-7.
PubMed
3) 岡部信彦, 多田有希, 安井良則. 急性脳炎・脳症の疫学. 日本臨牀 2011 ; 69 : 411-6.
Medical*Online
4) Okuno H, Yahata Y, Tanaka-Taya K, et al. Characteristics and outcomes of influenza-associated encephalopathy cases among children and adults in Japan, 2010-2015. Clin Infect Dis 2018 ; 66 : 1831-7.
PubMed
5) Morita A, Ishihara M, Kamei S, et al. Nationwide survey of influenza-associated acute encephalopathy in Japanese adults. J Neurol Sci 2019 ; 399 : 101-7.
PubMed
6) 水口雅, 葛西真梨子, 柴田明子, 星野愛, 厚生労働科学研究費補助金・難治性疾患政策研究事業・急性脳症研究班. インフルエンザ脳症の最新の動向 : 急性脳症の全国疫学調査の結果から. 小児科臨床 2019 ; 72 : 1395-9.
Medical*Online
7) Kawamura Y, Ohashi M, Ihira M, Hashimoto S, Taniguchi K, Yoshikawa T, et al. Nationwide survey of rotavirus-associated encephalopathy and sudden unexpected death in Japan. Brain Dev 2014 ; 36 : 601-7.
PubMed
8) Shima T, Okumura A, Kurahashi H, et al. A nationwide survey of norov rus-associated encephalitis/encephalopathy in Japan. Brain Dev 2019 ; 41 : 263-70.
 
9) Hoshino A, Saitoh M, Oka A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
10) Kasai M, Shibata A, Hoshino A, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
11) Ichinose F, Nakamura T, Kira R, et al. Incideice and risk factors of acute encephalopathy with biphasic seizures in febrile status epilepticus. Brain Dev 2022 ; 44 : 36-43.
PubMed
a) 塩見正司. ウイルス感染に関連する急性脳炎と急性脳症. 日本小児神経学会教育委員会, 編. 小児神経学の進歩 第29集. 東京 : 診断と治療社, 2000 : 2-19.
 
b) 森島恒雄. 小児における急性脳炎・脳症の病態・診断・治療に関する研究. 平成17～19年度科学研究費補助金 (基盤研究 (A)) 研究成果報告書. 2009.
 
c) 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 「重症・難治性急性脳症の病因解明と診療確立に向けた研究」班. 平成22年度研究報告 : 急性脳症の全国実態調査. 2011. https://encephalopathy.jp/nsurvey_data/h22.pdf
 
d) 厚生労働科学研究費 (難治性疾患政策研究事業) 「良質なエビデンスに基づく急性脳症の診療に向けた体制整備」研究班. 平成30年度研究報告 : 急性脳症の全国実態調査 (第二回. 平成29年度実施). 2019. https://encephalopathy.jp/nsurvey_data/h29_1.pdf
 
P.14 掲載の参考文献
1) Maegaki Y, Kurozawa Y, Tamasaki A, et al. Early predictors of status epilepticus-associated mortality and morbidity in children. Brain Dev 2015 ; 37 : 478-86.
PubMed
2) Nishiyama M, Nagase H, Tanaka T, et al. Short and long-term outcomes in children with suspected acute encephalopathy. Brain Dev 2016 ; 38 : 731-7.
 
3) Motojima Y, Nagura M, Asano Y, et al. Diagnostic and prognostic factors for acute encephalopathy. Pediatr Int 2016 ; 58 : 1188-92.
PubMed
4) Sasaki K, Nagase H, Maruyama A, et al. Clinical prediction rule for neurological sequelae due to acute encephalopathy : a medical community-based validation study in Harima, Japan. BMJ Open 2017 ; 7 : e016675.
PubMed
5) Matsubara Y, Osaka H, Yamagata T, Ae R, Shimizu J, Oguro N, et al. Long-term outcomes in motor and cognitive impairment with acute encephalopathy. Brain Dev 2018 ; 40 : 807-12.
PubMed
6) Hoshino A, Saitoh M, Oka A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
7) Kasai M, Shibata A, Hoshino A, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
8) Mizuguchi M. Influenza encephalopathy and related neuropsychiatric syndromes. Influenza Other Respir Viruses 2013 ; 7 (Suppl 3) : 67-71.
 
9) 水口雅, 葛西真梨子, 柴田明子, 星野愛, 厚生労働科学研究費補助金・難治性疾患政策研究事業・急性脳症研究班. インフルエンザ脳症の最新の動向 : 急性脳症の全国疫学調査の結果から. 小児科臨床 2019 ; 72 : 1395-9.
Medical*Online
a) 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 「重症・難治性急性脳症の病因解明と診療確立に向けた研究」班. 平成22年度研究報告 : 急性脳症の全国実態調査. 2011. https://encephalopathy.jp/nsurvey_data/h22.pdf
 
b) 厚生労働科学研究費 (難治性疾患政策研究事業) 「良質なエビデンスに基づく急性脳症の診療に向けた体制整備」班. 平成30年度研究報告 : 急性脳症の全国実態調査 (第二回. 平成29年度実施). 2019. https://encephalopathy.jp/nsurvey_data/h29_1.pdf
 
c) 厚生科学研究費補助金 (新興・再興感染症研究事業) インフルエンザの臨床経過中に発生する脳炎・脳症の疫学及び病態に関する研究. 平成12年度研究成果報告書, 2001.
 

第3章 急性脳症の診断と検査

P.23 掲載の参考文献
1) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf [閲覧日 : 2022. 10. 1]
 
2) Nagase H, Nakagawa T, Aoki K, et al. Therapeutic indicators of acute encephalopathy in patients with complex febrileres. Pediatr Int 2013 ; 55 : 310-4.
PubMed
3) 塩浜直, 金澤正樹, 安齋聡, ら. けいれん重積小児例の検討. 日児誌 2010 ; 114 : 956-60.
 
4) 布井博幸, 細矢光亮, 塩見正司, ら. 血清中チトクロムc 測定キットの急性脳症診断における臨床的評価. 医学と薬学 2009 ; 61 : 245-51.
Medical*Online
5) Tsukahara H, Fujii Y, Matsubara K, et al. Prognostic value of brain injury biomarkers in acute encephalitis/encephalopathy. Pediatr Int 2013 ; 55 : 461-4.
PubMed
6) Sasaki K, Nagase H, Maruyama A, et al. Clinical prediction rule for neurological sequelae due to acute encephalopathy : a medical community- based validation study in Harima, Japan. BMJ Open 2017 ; 7 : e016675.
PubMed
7) 井上元子, 山形崇倫, 門田行史, ら. 急性脳症40例の臨床的検討. 小児科臨床 2011 ; 64 : 2215-23.
Medical*Online
8) 井上岳司, 川脇壽, 温井めぐみ, ら. 当院救急外来でペーパレス脳波を施行した症例の臨床的検討. 脳と発達 2012 ; 44 : 305-9.
Medical*Online
9) 林下浩士, 久保田哲史, 有元秀樹, ら. 脳腫脹が進行する急性脳症の早期診断の指標-代謝性アシドーシスが2時間持続する症例は熱性痙攣ではない. 日本小児救急医学会雑誌 2011 ; 10 : 9-13.
 
10) 權藤健二郎, 花井敏男, 武本環美, 水野由美. 急性脳症の診断における尿中β2-microglobulin測定の有用性に関する検討. 脳と発達 2010 ; 42 : 233-4.
Medical*Online
11) Morita H, Hosoya M, Kato A, Kawasaki Y, Suzuki H, et al. Laboratory characteristics of acute encephalopathy with multiple organ dysfunctions. Brain Dev 2005 ; 27 : 477-82.
PubMed
12) Hosoya M, Nunoi H, Aoyama M, Kawasaki Y, Suzuki H, et al. Cytochrome c and tumor necrosis factor-alpha values in serum and cerebrospinal fluid of patients with influenza-associated encephalopathy. Pediatr Infect Dis J 2005 ; 24 : 467-70.
PubMed
13) 前垣義弘, 黒沢洋一, 林篤, ら. けいれん重積で発症する急性脳症の早期診断における臨床症状と検査所見. 日児誌 2006 ; 110 : 1550-7.
 
14) Kawahara Y, Morimoto A, Oh Y, et al. Serum and cerebrospinal fluid cytokines in children with acute encephalopathy. Brain Dev 2020 ; 42 : 185-91.
PubMed
15) Hirayama Y, Saito Y, Maegaki Y, Status Epilepticus Study Group. "Symptomatic" infection-associated acute encephalopathy in children with underlying neurological disorders. Brain Dev 2017 ; 39 : 243-7.
 
16) 玉井郁夫, 横田俊平, 後藤知英, 渡辺好宏, 和田敬仁, 小坂仁. インフルエンザ脳症発症例と未発症例における臨床徴候の比較. 日児誌 2017 ; 121 : 855-62.
 
17) Shiihara T, Miyake T, Izumi S, et al. Serum and CSF biomarkers in acute pediatric neurological disorders. Brain Dev 2014 ; 36 : 489-95.
PubMed
18) Hasegawa S, Matsushige T, Inoue H, et al. Serum and cerebrospinal fluid levels of visinin-like protein-1 in acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2014 ; 36 : 608-12.
PubMed
19) Shiihara T, Miyake T, Izumi S, et al. Serum and cerebrospinal fluid S100B, neuron-specific enolase, and total tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion : a diagnostic validity. Pediatr Int 2012 ; 54 : 52-5.
PubMed
20) Hayashi N, Okumura A, Kubota T, et al. Prognostic factors in acute encephalopathy with reduced subcortical diffusion. Brain Dev 2012 ; 34 : 632-9.
PubMed
21) Tanuma N, Miyata R, Kumada S, et al. The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010 ; 32 : 435-9.
PubMed
22) Ichiyama T, Suenaga N, Kajimoto M, et al. Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures. Brain Dev 2008 ; 30 : 47-52.
PubMed
23) 石井ちぐさ, 小田新, 野田雅裕, ら. けいれん重積型急性脳症における血清neuron-specific enolaseの変動. 小児科臨床 2007 ; 60 : 1702-6.
Medical*Online
24) Ichiyama T, Ito Y, Kubota M, Yamazaki T, Nakamura K, Furukawa S. Serum and cerebrospinal fluid levels of cytokines in acute encephalopathy associated with human herpesvirus-6 infection. Brain Dev 2009 ; 31 : 731-8.
PubMed
25) Tada H, Takanashi J, Okuno H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). J Neurol Sci 2015 ; 358 : 62-5.
PubMed
26) 天笠俊介, 松井彦郎, 宮本和, ら. 急性脳症 Glasgow Coma Scaleによるけいれん重積型脳症の早期診断. 日本集中治療医学会雑誌 2016 ; 23 : S285.
 
27) 市坂有基, 小原隆史, 平井克樹, ら. 二相性脳症における早期治療介入基準についての比較検討及びその活用. 日本小児救急医学会雑誌 2018 ; 17 : 396-400.
 
28) Yokochi T, Takeuchi T, Mukai J, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
29) Fujii Y, Yashiro M, Yamada M, et al. Serum procalcitonin levels in acute encephalopathy with biphasic seizures and late reduced diffusion. Dis Markers 2018 ; 2380179.
 
30) Oguri M, Saito Y, Fukuda C, et al. Distinguishing acute encephalopathy with biphasic seizures and late reduced diffusion from prolonged febrile seizures by acute phase EEG spectrum analysis. Yonago Acta Med 2016 ; 59 : 1-14.
PubMed
31) Lee S, Sanefuji M, Torio M, et al. Involuntary movements and coma as the prognostic marker for acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2016 ; 370 : 39-43.
PubMed
P.26 掲載の参考文献
1) 森島恒雄, 岡部信彦, 中村祐輔, ら. 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 小児科臨床 2009 ; 62 : 2483-528.
 
2) Tada H, Takanashi J, Okuno H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). J Neurol Sci 2015 ; 358 : 62-5.
PubMed
3) Yokochi T, Takeuchi T, Mukai J, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
4) 塩見正司. インフルエンザ脳症－臨床病型分類の試み. 小児科臨床 2000 ; 53 : 1739-46.
 
5) Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9.
PubMed
6) Mizuguchi M, Abe J, Mikkaichi K, et al. Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995 ; 58 : 555-61.
PubMed
7) Mizuguchi M, Yamanouchi H, Ichiyama T,Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 (4 Suppl) : 45-56.
 
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
P.32 掲載の参考文献
1) 木村清次, 根津敦夫, 大槻則行, 田中文雅, 武下草生子. 感染に伴う急性脳症35例の臨床的検討. 脳と発達 1998 ; 30 : 244-9.
Medical*Online
2) 水口雅. 急性脳症の分類とけいれん重積型. 脳と発達 2008 ; 40 : 117-21.
 
3) 塩見正司. インフルエンザ脳症の臨床スペクトラム. 小児内科 2003 ; 35 : 1676-80.
 
4) Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 (4 Suppl) : 45-56.
 
5) Mizuguchi M. Acute necrotizing encephalopathy of childhood : a novel form of acute encephalopathy prevalent in Japan and Taiwan. Brain Dev 1997 ; 19 : 81-92.
 
6) 水口雅. 急性壊死性脳症. 小児内科 2004 ; 36 : 1129-32.
 
7) 高梨潤一. 急性脳炎・脳症. 小児科診療 2018 ; 81 : 1049-57.
Medical*Online
8) Harada M, Hisaoka S, Mori K, Yoneda K, Noda S, Nishitani H. Differences in water diffusion and lactate production in two different types of postinfectious encephalopathy. J Magn Reson Imaging 2000 ; 11 : 559-63.
PubMed
9) Wong AM, Simon EM, Zimmerman RA,Wang HS, Toh CH, Ng SH. Acute nectrotizing encephalopathy of childhood : correlation of MR findings and clinical outcome. AJNR Am J Neuroradiol 2006 ; 27 : 1919-23.
 
10) Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9.
PubMed
11) Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009 ; 31 : 521-8.
PubMed
12) Tsubouchi Y, Itamura S, Saito Y, et al. Use of high b value diffusion-weighted magnetic resonance imaging in acute encephalopathy/encephalitis during childhood. Brain Dev 2018 ; 40 : 116-25.
 
13) Kuya K, Fujii S, Miyoshi F, et al. A case of acute encephalopathy with biphasic seizures and late reduced diffusion : Utility of arterial spin labeling sequence. Brain Dev 2017 ; 39 : 84-8.
PubMed
14) Uetani H, Kitajima M, Sugahara T, et al. Perfusion abnormality on three-dimensional arterial spin labeling in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 408 : 116558.
PubMed
15) Takanashi J, Tada H, Terada H, Barkovich AJ. Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. AJNR Am J Neuroradiol 2009 ; 30 : 132-5.
PubMed
16) Takanashi J, Mizuguchi M, Terai M, Barkovich AJ. Disrupted glutamate-glutamine cycle in acute encephalopathy with biphasic seizures and late reduced diffusion. Neuroradiology 2015 ; 57 : 1163-8.
PubMed
17) Yamanouchi H, Mizuguchi M. Acute infantile encephalopathy predominantly affecting the bilateral frontal lobes (AIEF) : a novel clinical category and its tentative diagnostic criteria. Epilepsy Res 2006 ; 70 (Suppl) : S263-8.
 
18) Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004 ; 63 : 1854-8.
PubMed
19) Takanashi J, Imamura A, Hayakawa F, Terada H. Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci 2010 ; 292 : 24-7.
 
20) Imamura T, Takanashi J, Yasugi J, Terada H, Nishimura A. Sisters with clinically mild encephalopathy with a reversible splenial lesion (MERS) -like features ; Familial MERS? J Neurol Sci 2010 ; 290 : 153-6.
 
21) 多田弘子, 高梨潤一. MERS. 五十嵐隆, 塩見正司, 編. 小児科臨床ピクシス 28. 急性脳炎・急性脳症. 東京 : 中山書店, 2011 : 184-7.
 
a) 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
b) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
P.39 掲載の参考文献
1) Lin JJ, Lin KL, Wang HS, Hsia SH, Wu CT. Effect of topiramate, in combination with lidocaine, and phenobarbital, in acute encephalitis with refractory repetitive partial seizures. Brain Dev 2009 ; 31 : 605-11.
PubMed
2) Shyu CS, Lee HF, Chi CS, Chen CH. Acute encephalitis with refractory, repetitive partial seizures. Brain Dev 2008 ; 30 : 356-61.
PubMed
3) Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS) : a peculiar form of childhood encephalitis. Acta Neurol Scand 2010 ; 121 : 251-6.
PubMed
4) Mizuguchi M, Abe J, Mikkaichi K, et al. Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995 ; 58 : 555-61.
PubMed
5) Maegaki Y, Kondo A, Okamoto R, et al. Clinical characteristics of acute encephalopathy of obscure origin : a biphasic clinical course is a common feature. Neuropediatrics 2006 ; 37 : 269-77.
PubMed
6) Okumura A, Suzuki M, Kidokoro H, et al. The spectrum of acute encephalopathy with reduced diffusion in the unilateral hemisphere. Eur J Paediatr Neurol 2009 ; 13 : 154-9.
PubMed
7) Harden A, Boyd SG, Cole G, Levin M. EEG features and their evolution in the acute phase of haemorrhagic shock and encehalopathy syndrome. Neuropediatrics 1991 ; 22 : 194-7.
 
8) Domachowske JB, Cunningham CK, Cummings DL, Crosley CJ, Hannan WP, Weiner LB. Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children. Pediatr Infect Dis J 1996 ; 15 : 871-5.
PubMed
9) Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001 ; 32 : 1674-84.
PubMed
10) Kolski H, Ford-Jones EL, Richardson S, et al. Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis 1998 ; 26 : 398-409.
PubMed
11) Fukuyama T, Yamauchi S, Amagasa S, et al. Early prognostic factors for acute encephalopathy with reduced subcortical diffusion. Brain Dev 2018 ; 40 : 707-13.
PubMed
12) Farias-Moeller R, Bartolini L, Staso K, et al. Early ictal and interictal patterns in FIRES : The sparks before the blaze. Epilepsia 2017 ; 58 : 1340-8.
PubMed
13) Mohammad SS, Soe SM, Pillai SC, et al. Etiological associations and outcome predictors of acute electroencephalography in childhood encephalitis. Clin Neurophysiol 2016 ; 127 : 3217-24.
PubMed
14) Okumura A, Nakano T, Fukumoto Y, et al. Delirious behavior in children with influenza : its clinical features and EEG findings. Brain Dev 2005 ; 27 : 271-4.
PubMed
15) Kashiwagi M, Tanabe T, Ooba C, et al. Differential diagnosis of delirious behavior in children with influenza. Brain Dev 2015 ; 37 : 618-24.
PubMed
16) PeBenito R, Cracco JB. Periodic lateralized epileptiform discharges in infants and children. Ann Neurol 1979 ; 6 : 47-50.
PubMed
17) Okumura A, Komatsu M, Abe S, et al. Amplitude-integrated electroencephalography in patients with acute encephalopathy with refractory, repetitive partial seizures. Brain Dev 2011 ; 33 : 77-82.
PubMed
18) Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush : a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012 ; 79 : 1094-100.
 
19) Accolla EA, Kaplan PW, Maeder-Ingvar M, Jukopila S, Rossetti AO. Clinical correlates of frontal intermittent rhythmic delta activity (FIR-DA). Clin Neurophysiol 2011 ; 122 : 27-31.
 
20) Watemberg N, Linder I, Dabby R, Blumkin L, Lerman-Sagie T. Clinical correlates of occipital intermittent rhythmic delta activity (OIRDA) in children. Epilepsia 2007 ; 48 : 330-4.
PubMed
21) Oguri M, Saito Y, Fukuda C, et al. Distinguishing Acute Encephalopathy with Biphasic Seizures and Late Reduced Diffusion from Prolonged Febrile Seizures by Acute Phase EEG Spectrum Analysis. Yonago Acta Med 2016 ; 59 : 1-14.
PubMed
22) Schreiber JM, Zelleke T, Gaillard WD, Kaulas H, Dean N, Carpenter JL. Continuous video EEG for patients with acute encephalopathy in a pediatric intensive care unit. Neurocrit Care 2012 ; 17 : 31-8.
 
23) Topjian AA, Gutierrez-Colina AM, Sanchez SM, et al. Electrographic status epilepticus is associated with mortality and worse short-term outcome in critically ill children. Crit Care Med 2013 ; 41 : 215-23.
PubMed
24) Abend NS, Gutierrez-Colina AM, Topjian AA, et al. Nonconvulsive seizures are common in critically ill children. Neurology 2011 ; 76 : 1071-7.
PubMed
25) Gwer S, Idro R, Fegan G, et al. Continuous EEG monitoring in Kenyan children with non-traumatic coma. Arch Dis Child 2012 ; 97 : 343-9.
PubMed
26) Abend NS, Topjian AA, Gutierrez-Colina AM, Donnelly M, Clancy RR, Dlugos DJ. Impact of continuous EEG monitoring on clinical management in critically ill children. Neurocrit Care 2011 ; 15 : 70-5.
PubMed
27) Gold JJ, Crawford JR, Glaser C, Sheriff H, Wang S, Nespeca M. The role of continuous electroencephalography in childhood encephalitis. Pediatr Neurol 2014 ; 50 : 318-23.
PubMed
28) Wagenman KL, Blake TP, Sanchez SM, et al. Electrographic status epilepticus and long-term outcome in critically ill children. Neurology 2014 ; 82 : 396-404.
PubMed
29) Payne ET, Zhao XY, Frndova H, et al. Seizure burden is independently associated with short term outcome in critically ill children. Brain 2014 ; 137 : 1429-38.
PubMed
30) Sansevere AJ, Duncan ED, Libenson MH, Loddenkemper T, Pearl PL, Tasker RC. Continuous EEG in Pediatric Critical Care : Yield and Efficiency of Seizure Detection. J Clin Neurophysiol 2017 ; 34 : 421-6.
PubMed
31) Yamaguchi H, Nagase H, Nishiyama M, et al. Nonconvulsive Seizure Detection by Reduced-Lead Electroencephalography in Children with Altered Mental Status in the Emergency Department. J Pediatr 2019 ; 207 : 213-9.e3.
 
32) Hellstrom-Westas L, Rosen I. Continuous brain-function monitoring : state of the art in clinical practice. Semin Fetal Neonatal Med 2006 ; 11 : 503-11.
PubMed
33) Shankaran S, Pappas A, McDonald SA, et al. Predictive value of an early amplitude integrated electroencephalogram and neurologic examination. Pediatrics 2011 ; 128 : e112-e20.
PubMed
34) Komatsu M, Okumura A, Matsui K, et al. Clustered subclinical seizures in a patient with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010 ; 32 : 472-6.
 
35) Stewart CP, Otsubo H, Ochi A, Sharma R, Hutchison JS, Hahn CD. Seizure identification in the ICU using quantitative EEG displays. Neurology 2010 ; 75 : 1501-8.
PubMed
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 

第4章 全身管理と体温管理療法 ( 脳低温・平温療法 )

P.45 掲載の参考文献
1) Shorvon S. Status Epilepticus : Its Clinical Features and Treatment in Children and Adults. Cambridge : Cambridge University Press, 1994.
 
2) EFA Working Group on Status Epilepticus. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on status epilepticus. JAMA 1993 ; 270 : 854-9.
 
3) Lowenstein DH. The Management of Refractory Status Epilepticus : An Update. Epilepsia 2006 ; 47 (Suppl 1) : 35-40.
 
4) Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001 ; 49 : 659-64.
 
5) Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015 ; 56 : 1515-23.
PubMed
6) Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus : a critical review of available therapies and a clinical treatment protocol. Brain 2011 ; 134 : 2802-18.
 
7) Smith KR, Kittler JT. The cell biology of synaptic inhibition in health and disease. Curr Opin Neurobiol 2010 ; 20 : 550-6.
PubMed
8) Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence : a randomised trial. Lancet 1999 ; 353 : 623-6.
PubMed
9) McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children : a randomised controlled trial. Lancet 2005 ; 366 : 205-10.
PubMed
10) McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2018 ; 1 : CD001905.
PubMed
11) Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children : prospective randomised study. BMJ 2000 ; 321 : 83-6.
PubMed
12) Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012 ; 366 : 591-600.
PubMed
13) Welch RD, Nicholas K, Durkalski-Mauldin VL, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia 2015 ; 56 : 254-62.
PubMed
14) Chamberlain LM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997 ; 13 : 92-4.
 
15) Hayashi K, Osawa M, Aihara M, et al. Efficacy of intravenous midazolam for status epilepticus in childhood. Pediatr Neurol 2007 ; 36 : 366-72.
PubMed
16) Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995 ; 37 : 682-8.
PubMed
17) Appleton R, Choonara I, Martland T, Phillips B, Scott R, Whitehouse W. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child 2000 ; 83 : 415-9.
PubMed
18) The Guideline Development Group, National Clinical Guideline Centre and NICE project team. The epilepsies : the diagnosis and management of the epilepsies in adults and children in primary andsecondary care. https://www.nice.org.uk/guidance/ng217 [閲覧日 : 2022. 10. 5]
 
19) Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. Brain Dev 2000 ; 22 : 239-42.
PubMed
20) 皆川公夫, 渡邊年秀. 小児のけいれん重積およびけいれん群発に対する8年間のmidazolam静注治療成績の検討. 脳と発達 2003 ; 35 : 484-90.
Medical*Online
21) 浜野晋一郎, 田中学, 望月美佳, 杉山延喜, 衞藤義勝. 小児けいれん重積症に対するmidazolam 治療の臨床的検討. 脳と発達 2003 ; 35 : 304-9.
 
22) Kapur J, Elm J, Chamberlain JM, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med 2019 ; 381 : 2103-13.
PubMed
23) Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT) : a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020 ; 395 : 1217-24.
PubMed
24) Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE) : a multicentre, open-label, randomised trial. Lancet 2019 ; 393 : 2125-34.
PubMed
25) Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT) : an open-label, multicentre, randomised controlled trial. Lancet 2019 ; 393 : 2135-45.
PubMed
26) Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus : a randomized, open labeled pilot study. J Neurol 2012 ; 259 : 645-8.
PubMed
27) Strzelczyk A, Zollner JP, Willems LM, et al. Lacosamide in status epilepticus : Systematic review of current evidence. Epilepsia 2017 ; 58 : 933-50.
PubMed
28) Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol 2002 ; 17 : 106-10.
PubMed
29) van Gestel JPJ, Blusse van Oud-Alblas HJ, Malingre M, Ververs FFT, Braun KPJ, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005 ; 65 : 591-2.
PubMed
30) Gilbert DL, Gartside PS, Glauser TA. Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children : a meta-analysis. J Child Neurol 1999 ; 14 : 602-9.
PubMed
31) Gilbert DL, Glauser TA. Complications and costs of treatment of refractory generalized convulsive status epilepticus in children. J Child Neurol 1999 ; 14 : 597-601.
 
32) Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epileptics. Neurocrit Care 2012 ; 17 : 3-23.
 
P.50 掲載の参考文献
1) Pearson G, Shann F, Barry P, et al. Should paediatric intensive care be centralized? Trent versus Victoria. Lancet 1997 ; 349 : 1213-7.
PubMed
2) 武井健吉, 清水直樹, 松本尚, ら. 小児重症患者の救命には小児集中治療施設への患者集約が必要である. 日本救急医学会雑誌 2008 ; 19 : 201-7.
 
3) Pfenninger J, Kaiser G, Lutschg J, Sutter M. Treatment and outcome of the severely head injured child. Intensive Care Med 1983 ; 9 : 13-6.
PubMed
4) Esparza J, M-Portillo J, Sarabia M, Yuste JA, Roger R, Lamas E. Outcome in children with severe head injuries. Childs Nerv Syst 1985 ; 1 : 109-14.
 
5) Alberico AM, Ward JD, Choi SC, Marmarou A, Young HF. Outcome after severe head injury. Relationship to mass lesions, diffuse injury, and ICP course in pediatric and adult patients. J Neurosurg 1987 ; 67 : 648-56.
PubMed
6) Kasoff SS, Lansen TA, Holder D, Filippo JS. Aggressive physiologic monitoring of pediatric head trauma patients with elevated intracranial pressure. Pediatr Neurosci 1988 ; 14 : 241-9.
PubMed
7) Grinkeviciute DE, Kevalas R, Matukevicius A, Ragaisis V, Tamasauskas A. Significance of intracranial pressure and cerebral perfusion pressure in severe pediatric traumatic brain injury. Medicina (Kaunas) 2008 ; 44 : 119-25.
PubMed
8) Downard C, Hulka F, Mullins RJ, et al. Relationship of cerebral perfusion pressure and survival in pediatric brain-injured patients. J Trauma 2000 ; 49 : 654-8.
PubMed
9) Fisher B, Thomas D, Peterson B. Hypertonic saline lowers raised intracranial pressure in children after head trauma. J Neurosurg Anesthesiol 1992 ; 4 : 4-10.
 
10) Peterson B, Khanna S, Fisher B, Marshall L. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000 ; 28 : 1136-43.
PubMed
11) Dominguez TE, Priestly MA, Huh JW. Caution should be exercised when maintaining a serum sodium level > 160 meq/L. Crit Care Med 2004 ; 32 : 1438-40.
 
12) Bratton SL, Chestnut RM, Ghajar J, et al. Guideline for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma 2007 ; 24 (Suppl 1) : S14-S20.
 
13) Pittman T, Bucholz R, Williams D. Efficacy of barbiturates in the treatment of resistant intracranial hypertension in severely head-injured children. Pediatr Neurosci 1989 ; 15 : 13-7.
PubMed
14) Kasoff SS, Lansen TA, Holder D, Filippo JS. Aggressive physiologic monitoring of pediatric head trauma patients with elevated intracranial pressure. Pediatr Neurosci 1988 ; 14 : 241-9.
PubMed
15) Skippen P, Seear M, Poskitt K, et al. Effect of hyperventilation on regional cerebral blood flow in head-injured children. Crit Care Med 1997 ; 25 : 1402-9.
PubMed
16) Curry R, Hollingworth W, Ellenbogen RG, Vavilala MS. Incidence of hypo- and hypercarbia in severe traumatic brain injury before and after 2003 pediatric guidelines. Pediatr Crit Care Med 2008 ; 9 : 141-6.
PubMed
17) Abend NS, Topjian AA, Gutierrez-Colina AM, Donnelly M, Clancy RR, Dlugos DJ. Impact of continuous EEG monitoring on clinical management in critically ill children. Neurocrit Care 2011 ; 15 : 70-5.
PubMed
18) Topjian AA, Gutierrez-Colina AM, Sanchez SM, et al. Electrographic status epilepticus is associated with mortality and worse short-term outcome in critically ill children. Crit Care Med 2013 ; 41 : 215-23.
PubMed
19) Skillman HE, Wischmeyer PE. Nutrition therapy in critically ill infants and children. JPEN J Parenter Enteral Nutr 2008 ; 32 : 520-34.
PubMed
a) AHA. PALSプロバイダーマニュアル AHAガイドライン 2020 準拠. 東京 : シナジー, 2021.
 
b) Kochanek PM, Carney N, Adelson PD, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents--second edition. Pediatr Crit Care Med 2012 ; 13 (Suppl 1) : S1-82.
 
c) 山内秀雄, 市山高志, 大澤真木子, ら. 小児の急性脳症. 日本医薬情報センター, 編. 重篤副作用疾患別対応マニュアル 第5集. 東京 : 日本医薬情報センター, 2011 : 58-72.
 
P.54 掲載の参考文献
1) Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002 ; 346 : 549-56.
 
2) Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002 ; 346 : 557-63.
PubMed
3) Moler FW, Silverstein FS, Holubkov R, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest in children. N Engl J Med 2015 ; 372 : 1898-908.
PubMed
4) Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009 ; 361 : 1349-58.
PubMed
5) Azzopardi D, Strohm B, Marlow N, et al. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med 2014 ; 371 : 140-9.
PubMed
6) Zhou WH, Cheng GQ, Shao XM, et al. Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy : a multicenter randomized controlled trial in China. J Pediatr 2010 ; 157 : 367-72, 372.e1-3.
 
7) Perlman JM, Wyllie J, Kattwinkel J, et al. Part 11 : Neonatal resuscitation : 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2010 ; 122 (Suppl 2) : S516-S38.
 
8) Fiser DH. Assessing the outcome of pediatric intensive care. J Pediatr 1992 ; 121 : 68-74.
PubMed
9) 佐治洋介, 永瀬裕朗, 青木一憲, ら. 小児急性脳炎・脳症に対するデキサメサゾン併用脳低温療法の神経学的予後に対する有用性の検討. 日本小児救急医学会雑誌 2011 ; 10 : 22-6.
 
10) Hoshide M, Yasudo H, Inoue H, et al. Efficacy of hypothermia therapy in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2020 ; 42 : 515-22.
PubMed
11) Imataka G, Wake K, Yamanouchi H, Ono K, Arisaka O. Brain hypothermia therapy for status epilepticus in childhood. Eur Rev Med Pharmacol Sci 2014 ; 18 : 1883-8.
PubMed
12) Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33℃ versus 36℃ after cardiac arrest. N Engl J Med 2013 ; 369 : 2197-206.
 
13) Kawano G, Iwata O, Iwata S, et al. Determinants of outcomes following acute child encephalopathy and encephalitis : pivotal effect of early and delayed cooling. Arch Dis Child 2011 ; 96 : 936-41.
PubMed
14) Imataka G, Wake K, Suzuki M, Yamanouchi H, Arisaka O. Acute encephalopathy associated with hemolytic uremic syndrome caused by Escherichia coli O157 : H7 and rotavirus infection. Eur Rev Med Pharmacol Sci 2015 ; 19 : 1842-4.
 
15) Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with stroke and neurologic injury : a comprehensive meta-analysis. Stroke 2008 ; 39 : 3029-35.
PubMed
16) Zeiner A, Holzer M, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med 2001 ; 161 : 2007-12.
PubMed
17) Bro-Jeppesen J, Hassager C, Wanscher M, et al. Post-hypothermia fever is associated with increased mortality after out-of-hospital cardiac arrest. Resuscitation 2013 ; 84 : 1734-40.
PubMed
18) Leary M, Grossestreuer AV, Iannacone S, et al. Pyrexia and neurologic outcomes after therapeutic hypothermia for cardiac arrest. Resuscitation 2013 ; 84 : 1056-61.
PubMed
19) Bro-Jeppesen J, Annborn M, Hassager C, et al. Hemodynamics and vasopressor support during targeted temperature management at 33℃ Versus 36℃ after out-of-hospital cardiac arrest : a post hoc study of the target temperature management trial*. Crit Care Med 2015 ; 43 : 318-27.
 
20) Moler FW, Silverstein FS, Holubkov R, et al. Therapeutic Hypothermia after In-Hospital Cardiac Arrest in Children. N Engl J Med 2017 ; 376 : 318-29.
PubMed
21) Duff JP, Topjian AA, Berg MD, et al. 2019 American Heart Association Focused Update on Pediatric Advanced Life Support : An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2020 ; 145 : e20191361.
 
22) Nishiyama M, Tanaka T, Fujita K, Maruyama A, Nagase H. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
23) Murata S, Kashiwagi M, Tanabe T, et al. Targeted temperature management for acute encephalopathy in a Japanese secondary emergency medical care hospital. Brain Dev 2016 ; 38 : 317-23.
 
24) Tanaka T, Nagase H, Yamaguchi H, et al. Predicting the outcomes of targeted temperature management for children with seizures and/or impaired consciousness accompanied by fever without known etiology. Brain Dev 2019 ; 41 : 604-13.
PubMed
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 

第5章 代謝異常による急性脳症

P.62 掲載の参考文献
1) Clarke JTR. Summary of major causes of acute encephalopathy. In : Clarke JTR, ed., A Clinical Guide to Inherited Metabolic Diseases. 3rd ed, Cambridge : Cambridge University Press, 2006 : 53-89.
 
2) Initial laboratory investigations. In : Hoffmann GF, Nyhan WL, Zschocke J, Kahler SG, Mayatepek E, eds., Inherited metabolic diseases, Philadelphia : Lippncott Williams & Wilkins, 2002 : 34.
 
3) Haberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders : First revision. J Inherit Metab Dis 2019 ; 42 : 1192-230.
PubMed
4) 村山圭, 鶴岡智子. 急性期症状に対する治療のポイント : 高アンモニア血症. 小児科診療 2013 ; 59 : 59-64.
Medical*Online
5) Brusilow SW, Horwich AL. Urea cycle enzymes. In : Scriver CR, Beaudet AL, Sly WS, eds., The metabolic and molecular basis of inherited disease, 8th ed. New York : McGraw-Hill, 2001 : 1909-1963.
 
6) Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004 ; 81 (Suppl 1) : S86-S91.
 
7) Chuang DT, Shih VE. Maple syrup urine disease. In : Scriver CR, Beaudet AL, Sly WS, Valle D, eds., The metabolic and molecular bases of inherited disease. New York : McGraw-Hill, 2001 : 1971-2005.
 
8) 木村昭彦. ライ症候群. 肝胆膵 2007 ; 55 : 229-35.
Medical*Online
9) チョッケ& ホフマン, 著. 松原洋一, 監訳. 小児代謝疾患マニュアル. 改訂第2版, 東京 : 診断と治療社, 2013 : 30-1.
 
10) Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003 ; 126 : 1905-12.
PubMed
11) Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome : clinical features and biochemical and DNA abnormalities. Ann Neurol 1996 ; 39 : 343-51.
PubMed
12) Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes : a distinctive clinical syndrome. Ann Neurol 1984 ; 16 : 481-8.
PubMed
13) 藤浪綾子, 村山圭, 鶴岡智子, 山崎太郎, 高柳正樹, 大竹明. ミトコンドリア呼吸鎖複合体異常症における肝疾患の現状. 日児栄消肝誌 2011 ; 25 : 69-74.
 
14) 飯塚高浩. MELASにおける脳卒中様発作. 村山圭, 小坂仁, 三牧正和, 編. 遺伝子医学 (MOOK 35) : ミトコンドリアと病気. 大阪 : メディカルドゥ, 2020 : 74-8.
 
a) 日本先天代謝異常学会, 編. 新生児マススクリーニング対象疾患等診療ガイドライン 2019. 東京 : 診断と治療社, 2019.
 
P.68 掲載の参考文献
1) Initial laboratory investigations. In : Hoffmann GF, Nyhan WL, Zschocke J, Kahler SG, Mayatepek E, eds., Inherited metabolic diseases. Philadelphia : Lippincott Williams & Wilkins, 2002 : 34.
 
2) 高柳正樹. 代謝救急. 五十嵐隆, 高柳正樹, 編. 小児科臨床ピクシス 23. 見逃せない先天代謝異常. 東京 : 中山書店, 2010 : 2-4.
 
3) チョッケ & ホフマン, 著. 松原洋一, 監訳. 小児代謝疾患マニュアル. 改訂第2版. 東京 : 診断と治療社, 2013 : 1-16, 127-35.
 
4) Clarke JTR. Summary of major causes of acute encephalopathy. In : Clarke JTR, ed., A Clinical Guide to Inherited Metabolic Diseases. 3rd ed, Cambridge : Cambridge University Press, 2006 : 53-89.
 
5) Brusilow SW, Horwich AL. Urea cycle enzymes. In : Scriver CR, Beaudet AL, Sly WS, eds., The metabolic and molecular basis of inherited disease. 8th ed, New York : McGraw-Hill, 2001 : 1909-63.
 
6) Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004 ; 81 (Suppl 1) : S86-S91.
 
7) Endo F, Matsuura T, Yanagida K, Matsuda I. Clinical manifestation of inborn errors of ths urea cycle and related metabolic disorders during childhood. J Nutr 2004 ; 134 (6 Suppl) : 1605S-9S.
 
8) Haberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012 ; 7 : 32.
PubMed
9) Sugiyama Y, Shimura M, Ogawa-Tominaga M, et al. Therapeutic effect of N-carbamylglutamate in CPS1 deficiency. Mol Genet Metab Rep 2020 ; 24 : 100622.
 
10) 信國好俊, 三渕浩, 犬童康弘, ら. メープルシロップ尿症 : 分枝鎖ケト酸脱水素酵素複合体の分子病理学. 生化学 1992 ; 64 : 67-82.
 
11) Mitsubuchi H, Owada M, Endo F. Markers associated with inborn errors of metabolism of branched-chain amino acids and their relevance to upper levels of intake in healthy people : an implication from clinical and molecular investigations on maple syrup urine disease. J Nutr 2005 ; 135 (6 Suppl) : 1565S-70S.
 
12) 三渕浩, 信國好俊, 林田由美, ら. メープルシロップ尿症の遺伝子解析. 臨床病理 1993 ; 41 : 484-91.
Medical*Online
13) Morris AAM, Spiekerkoetter U. Disorders of mitochondrial fatty acid oxidation and related metabolic pathways. In : Saudubray JM, van den Berghe G, Walter JH, eds., Inborn Metabolic Diseases. 5th ed, Berlin : Springer, 2011 : 201-16.
 
14) Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002 ; 59 : 1406-11.
PubMed
15) Kirby DM, Crawford M, Cleary MA, Dahl HH, Dennett X, Thorburn DR. Respiratory chain complex I deficiency : an underdiagnosed energy generation disorder. Neurology 1999 ; 52 : 1255-64.
PubMed
16) Thorburn DR, Chow CW, Kirby DM. Respiratory chain enzyme analysis in muscle and liver. Mitochondrion 2004 ; 4 : 363-75.
PubMed
17) Gibson K, Halliday JL, Kirby DM, Yaplito-Lee J, Thorburn DR, Boneh A. Mitochondrial oxidative phosphorylation disorders presenting in neonates : clinical manifestations and enzymatic and molecular diagnoses. Pediatrics 2008 ; 122 : 1003-8.
PubMed
18) Ohtake A, Murayama K, Mori M, et al. Diagnosis and molecular basis of mitochondrial respiratory chain disorders : exome sequencing for disease gene identification. Biochim Biophys Acta 2014 ; 1840 : 1355-9.
PubMed
19) 高柳正樹. カルニチン代謝異常症. 小児内科 2006 ; 38 (Suppl) : 167.
 
a) 日本先天代謝異常学会, 編. 新生児マススクリーニング対象疾患等診療ガイドライン 2019. 東京 : 診断と治療社, 2019.
 
b) 日本ミトコンドリア学会, 編. ミトコンドリア病診療マニュアル 2017. 東京 : 診断と治療社, 2017.
 
P.72 掲載の参考文献
1) 中川俊輔, 内藤悦雄. 幼児期から筋力低下を繰り返し6歳時にLeigh脳症を発症したビタミンB1反応性ピルビン酸脱水素酵素複合体異常症の1例. 脳と発達 2014 ; 46 (Suppl) : S375.
 
2) Fassone E, Wedatilake Y, DeVile CJ, Chong WK, Carr LJ, Rahman S. Treatable Leigh-like encephalopathy presenting in adolescence. BMJ Case Rep 2013 ; 2013 : 200838.
PubMed
3) Ortigoza-Escobar JD, Serrano M, Molero M, et al. Thiamine transporter-2 deficiency : outcome and treatment monitoring. Orphanet J Rare Dis 2014 ; 9 : 92.
PubMed
4) Banka S, de Goede C, Yue WW, et al. Expanding the clinical and molecular spectrum of thiamine pyrophosphokinase deficiency : a treatable neurological disorder caused by TPK1 mutations. Mol Genet Metab 2014 ; 113 : 301-6.
PubMed
5) 新井紗記子, 原紳也, 加藤耕治, ら. Wernicke脳症の小児2例. 小児科臨床 2014 ; 67 : 2137-43.
Medical*Online
6) 塩田勉, 渡邉誠司, 京極敬典, 加藤寛幸, 奥村良法, 愛波秀男. 多量のイオン飲料摂取によりWernicke脳症を呈した乳児例. 日児誌 2014 ; 118 : 930-6.
 
7) 平木彰佳, 菊地正広. イオン飲料の多飲によるビタミンB1欠乏症からWernicke脳症を発症した2例. 脳と発達 2014 ; 46 : 34-8.
Medical*Online
8) 福山哲広, 武居裕子, 奥野慈雨, ら. イオン飲料多飲によるWernicke脳症の1例. 日児誌 2013 ; 117 : 1668-69.
 
9) Lallas M, Desai J. Wernicke encephalopathy in children and adolescents. World J Pediatr 2014 ; 10 : 293-8.
PubMed
10) 西山将広, 田中司, 藤田杏子, ら. ピボキシル基含有抗菌薬3日間投与によるカルニチン欠乏が関与した急性脳症の1例. 日児誌 2014 ; 118 : 812-8.
 
11) Hori T, Fukao T, Kobayashi H, et al. Carnitine palmitoyltransferase 2 deficiency : the time-course of blood and urinary acylcarnitine levels during initial L-carnitine supplementation. Tohoku J Exp Med 2010 ; 221 : 191-5.
PubMed
12) Kobayashi Y, Ishikawa N, Tsumura M, et al. Acute severe encephalopathy related to human herpesvirus-6 infection in a patient with carnitine palmitoyltransferase 2 deficiency carrying thermolabile variants. Brain Dev 2013 ; 35 : 449-53.
 
13) Sakai E, Yamanaka G, Kawashima H, et al. A case of recurrent acute encephalopathy with febrile convulsive status epilepticus with carnitine palmitoyltransferase II variation. Neuropediatrics 2013 ; 44 : 218-21.
PubMed
14) 中村雄作, 山田郁子, 阪本光. MELAS脳卒中様発作に, Edaravone, CoQ10 大量療法が有効でなくarginine療法が奏効した成人MELASの1症例. 神経治療学 2008 ; 25 : 310.
 
15) Kaji S, Murayama K, Nagata I, et al. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol Genet Metab 2009 ; 97 : 292-6.
PubMed
16) Naini A, Lewis V-J, Hirano M, DiMauro S. Primary coenzyme Q10 deficiency and the brain. Biofactors 2003 ; 18 : 145-52.
PubMed
17) Bentinger M, Dallner G, Chojnacki T, Swiezewska E. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med 2003 ; 34 : 563-75.
PubMed
18) 田中藤樹, 長尾雅悦. リボフラビン反応性一過性新生児グルタル酸血症II 型の1例. 特殊ミルク情報 2013 ; 49 : 39-43.
 
19) Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005 ; 64 : 710-2.
PubMed
20) Koga Y, Povalko N, Nishioka J, Katayama K, Yatsuga S, Matsuishi T. Molecular pathology of MELAS and L-arginine effects. Biochim Biophys Acta 2012 ; 1820 : 608-14.
PubMed
21) 古賀靖敏. ミトコンドリア脳筋症治療の現況と展望. 日本臨牀 2014 ; 72 : 175-84.
Medical*Online
22) Ganetzky RD, Falk MJ. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab 2018 ; 123 : 301-8.
PubMed
23) Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS : a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 2019 ; 90 : 529-36.
 
24) Fukui KO, Kubota M, Terashima H, Ishiguro A, Kashii H. Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion : A case control study. Brain Dev 2019 ; 41 : 618-24.
PubMed
25) Omata T, Fujii K, Takanashi J, et al. Drugs indicated for mitochondrial dysfunction as treatments for acute encephalopathy with onset of febrile convulsive status epileptics. J Neurol Sci 2016 ; 360 : 57-60.
PubMed

第6章 全身性炎症反応による急性脳症

P.77 掲載の参考文献
1) Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference : definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005 ; 6 : 2-8.
 
2) 長谷川俊史, 市山高志. 敗血症. 小児科学レクチャー 2013 ; 3 : 316-22.
 
3) Suarez-Santamaria M, Santolaria F, Perez-Ramirez A, et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. Eur Cytokine Netw 2010 ; 21 : 19-26.
 
4) Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influenza-associated encephalopathy. Pediatr Infect Dis J 2008 ; 27 : 384-9.
PubMed
5) 權藤健二郎, 花井敏男, 武本環美, 水野由美. 急性脳症の診断における尿中β2-microglobulin 測定の有用性に関する検討. 脳と発達 2010 ; 42 : 233-4.
Medical*Online
6) Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology 2001 ; 57 : 295-9.
PubMed
7) Morita H, Hosoya M, Kato A, Kawasaki Y, Suzuki H. Laboratory characteristics of acute encephalopathy with multiple organ dysfunctions. Brain Dev 2005 ; 27 : 477-82.
PubMed
8) Ichiyama T, Endo S, Kaneko M, Isumi H, Matsubara T, Furukawa S. Serum cytokine concentrations of influenza-associated acute necrotizing encephalopathy. Pediatr Int 2003 ; 45 : 734-6.
PubMed
9) Ichiyama T, Morishima T, Isumi H, Matsufuji H, Matsubara T, Furukawa S. Analysis of cytokine levels and NF-κB activation in peripheral blood mononuclear cells in influenza virus-associated encephalopathy. Cytokine 2004 ; 27 : 31-7.
 
10) Kawahara Y, Morimoto A, Oh Y, et al. Serum and cerebrospinal fluid cytokines in children with acute encephalopathy. Brain Dev 2020 ; 42 : 185-91.
PubMed
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の治療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
b) 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
P.78 掲載の参考文献
1) 小林慈典, 富樫武弘, 水口雅, ら. インフルエンザ脳症特殊治療の全国調査. 日児誌 2007 ; 111 : 659-65.
 
2) Okumura A, Mizuguchi M, Kidokoro H, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 211-7.
PubMed
3) 市山高志. 病態を踏まえた治療戦略. Neuroinfection 2013 ; 18 : 74-9.
 
4) 鳥巣浩幸, 原寿郎. インフルエンザ脳症. BRAIN and NERVE 2015 ; 67 : 859-69.
 
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
b) 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
P.79 掲載の参考文献
1) Ichiyama T, Ueno Y, Hasegawa M, Niimi A, Matsubara T, Furukawa S. Intravenous immunoglobulin inhibits NF- kappa B activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol 2004 ; 369 : 428-33.
PubMed
2) Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S. An immunoglobulin agent (IVIG) inhibits NF- kappa B activation in cultured endothelial cells of coronary arteries in vitro. Inflamm Res 2004 ; 53 : 253-6.
PubMed
3) 小林慈典, 富樫武弘, 水口雅, ら. インフルエンザ脳症特殊治療の全国調査. 日児誌 2007 ; 111 : 659-65.
 
4) Okumura A, Mizuguchi M, Kidokoro H, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 211-7.
PubMed
5) 鳥巣浩幸, 原寿郎. インフルエンザ脳症. BRAIN and NERVE 2015 ; 67 : 859-69.
 
6) Matsuda K, Hirasawa H, Oda S, Shiga H, Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 2001 ; 5 : 306-14.
PubMed
7) Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. Ther Apher 2002 ; 6 : 419-24.
PubMed
8) Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis : a randomized controlled trial. Crit Care Med 2009 ; 37 : 803-10.
PubMed
9) 早野駿佑, 天本正乃, 高野健一, 神薗淳司, 山下由理子, 友納優子. 積極的な治療介入を行い予後良好な経過を辿った急性壊死性脳症. 日小児救急医会誌 2020 ; 19 : 60-4.
 
10) Matsuda K, Moriguchi T, Harii N,Goto J. Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfus Apher Sci 2009 ; 40 : 49-53.
 
11) 和合正邦, 下岡武史. 血液浄化療法. 日本臨牀 2011 ; 69 : 534-40.
Medical*Online
12) 平野浩一. 血液浄化療法. 小児内科 2013 ; 45 : 242-44.
Medical*Online
a) 伊藤克己, 監. 小児急性血液浄化療法マニュアル. 東京 : 医学図書出版, 2002.
 
b) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の治療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
c) 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
d) 伊藤秀一, 和田尚弘, 監. 小児急性血液浄化療法ハンドブック. 東京 : 東京医学社, 2013.
 
P.84 掲載の参考文献
1) Mizuguchi M, Abe J, Mikkaichi K, et al. Acute necrotising encephalopathy of childhood : a new syndrome presenting with multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995 ; 58 : 555-61.
PubMed
2) Hoshino A, Saitoh M, Oka A, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes. Brain Dev 2012 ; 34 : 337-43.
PubMed
3) Mizuguchi M. Acute necrotizing encephalopathy of childhood : a novel form of acute encephalopathy prevalent in Japan and Taiwan. Brain Dev 1997 ; 19 : 81-92.
 
4) Kim JH, Kim IO, Lim MK, et al. Acute necrotizing encephalopathy in Korean infants and children : imaging findings and diverse clinical outcome. Korean J Radiol 2004 ; 5 : 171-7.
PubMed
5) Seo HE, Hwang SK, Choe BH, Cho MH, Park SP, Kwon S. Clinical spectrum and prognostic factors of acute necrotizing encephalopathy in children. J Korean Med Sci 2010 ; 25 : 449-53.
 
6) Lee CG, Kim JH, Lee M, Lee J. Clinical outcome of acute necrotizing encephalopathy in related to involving the brain stem of single institution in Korea. Korean J Pediatr 2014 ; 57 : 264-70.
 
7) Lim HY, Ho VPY, Lim TCC, Thomas T, Chan DWS. Serial outcomes in acute necrotising encephalopathy of childhood : A medium and long term study. Brain Dev 2016 ; 38 : 928-36.
 
8) Chow CK, Ma CKL. Presentation and Outcome of Acute Necrotizing Encephalopathy of Childhood : A 10-Year Single-Center Retrospective Study From Hong Kong. J Child Neurol 2020 ; 35 : 674-80.
PubMed
9) Williams TA, Brunsdon RK, Burton KLO, et al. Neuropsychological outcomes of childhood acute necrotizing encephalopathy. Brain Dev 2019 ; 41 : 894-900.
PubMed
10) Neilson DE, Adams MD, Orr CMD, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet 2009 ; 84 : 44-51.
PubMed
11) Nishimura N, Higuchi Y, Kimura N, et al. Familial acute necrotizing encephalopathy without RANBP2 mutation : Poor outcome. Pediatr Int 2016 ; 58 : 1215-8.
PubMed
12) Hoshino A, Saitoh M, Miyagawa T, et al. Specific HLA genotypes confer susceptibility to acute necrotizing encephalopathy. Genes Immun 2016 ; 17 : 367-9.
PubMed
13) Mizuguchi M, Hayashi M, Nakano I, et al. Concentric structure of thalamic lesions in acute necrotizing encephalopathy. Neuroradiology 2002 ; 44 : 489-93.
PubMed
14) Albayram S, Bilgi Z, Selcuk H, et al. Diffusion-weighted MR imaging findings of acute necrotizing encephalopathy. AJNR Am J Neuroradiol 2004 ; 25 : 792-7.
PubMed
15) Tenembaum SN. Acute disseminated encephalomyelitis. Handb Clin Neurol 2013 ; 112 : 1253-62.
PubMed
16) Kurahashi N, Tsuji T, Kato T, et al. Thalamic lesions in acute encephalopathy with biphasic seizures and late reduced diffusion. Pediatr Neurol 2014 ; 51 : 701-5.
PubMed
17) Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9.
PubMed
18) Okumura A, Mizuguchi M, Aiba H, Tanabe T, Tsuji T, Ohno A. Delirious behavior in children with acute necrotizing encephalopathy. Brain Dev 2009 ; 31 : 594-9.
PubMed
19) Yamamoto H, Okumura A, Natsume J, Kojima S Mizuguchi M. A severity score for acute necrotizing encephalopathy. Brain Dev 2015 ; 37 : 322-7.
PubMed
20) Okumura A, Mizuguchi M, Kidokoro H, et al. Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin. Brain Dev 2009 ; 31 : 221-7.
PubMed
21) 池田裕一, 赤城邦彦, 高橋英彦, 奥山伸彦, 鹿間芳明, 田中祐吉. 肝障害, 腎不全合併の急性壊死性脳症患児への持続血液濾過透析療法. 日児誌 2002 ; 106 : 81-4.
 
22) 小山智弘, 田中具治, 溝田敏幸, ら. 著明な肝機能障害を合併した急性壊死性脳症の一例. 日本集中治療医学会雑誌 2013 ; 20 : 285-6.
 
23) Koh JC, Murugasu A, Krishnappa J, Thomas T. Favorable outcomes with early interleukin 6 receptor blockade in severe acute necrotizing encephalopathy of childhood. Pediatr Neurol 2019 ; 98 : 80-4.
PubMed
a) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 

第7章 けいれん重積を伴う急性脳症

P.94 掲載の参考文献
1) 厚生労働科学研究費 (難治性疾患政策研究事業) 「良質なエビデンスに基づく急性脳症の診療確立に向けた体制整備」研究班. 平成30年度研究報告 : 急性脳症の全国実態調査 (第二回. 平成29年度実施). 2019. https://encephalopathy.jp/nsurvey_data/h29_1.pdf [閲覧日 : 2022. 11. 4]
 
2) Kasai M, Shibata A, Hoshino A, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
3) Hirayama Y, Saito Y, Maegaki Y, Status Epilepticus Study Group. "Symptomatic" infection-associated acute encephalopathy in children with underlying neurological disorders. Brain Dev 2017 ; 39 : 243-7.
 
4) Ichinose F, Nakamura T, Kira R, et al. Incideice and risk factors of acute encephalopathy with biphasic seizures in febrile status epilepticus. Brain Dev 2022 ; 44 : 36-43.
PubMed
5) Takanashi J, Oba H, Barkovich AJ, et al. Diffusion MRI abnormalities after prolonged febrile seizures with encephalopathy. Neurology 2006 ; 66 : 1304-9.
PubMed
6) Takanashi J, Tada H, Terada H, Barkovich AJ. Excitotoxicity in acute encephalopathy with biphasic seizures and late reduced diffusion. AJNR Am J Neuroradiol 2009 ; 30 : 132-5.
PubMed
7) Takase N, Igarashi N, Taneichi H, et al. Infantile traumatic brain injury with a biphasic clinical course and late reduced diffusion. J Neurol Sci 2018 ; 390 : 63-6.
PubMed
8) Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009 ; 31 : 521-8.
PubMed
9) Takanashi J, Tsuji M, Amemiya K, Tada H, Barkovich A. Mild influenza encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2007 ; 256 : 86-9.
PubMed
10) Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand 2007 ; 115 (4 Suppl) : 45-56.
 
11) 水口雅. 急性脳症の分類とけいれん重積型. 脳と発達 2008 ; 40 : 117-21.
 
12) 塩見正司. インフルエンザ脳症の臨床スペクトラム. 小児内科 2003 ; 35 : 1676-81.
 
13) 高梨潤一. けいれん重積型 (二相性) 急性脳症 (AESD) の病態・診断・治療. 小児科 2021 ; 62 : 939-48.
 
14) Komatsu M, Okumura A, Matsui K, et al. Clustered subclinical seizures in a patient with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010 ; 32 : 472-6.
 
15) Saito T, Saito Y, Sugai K, et al. Late-onset epilespsy in children with acute febrile encephalopathy with prolonged convulsions : a clinical and encephalographic study. Brain Dev 2013 ; 35 : 531-9.
 
16) 前垣義弘. 二相性脳症/けいれん重積型急性脳症. 小児科診療 2011 ; 74 : 950-4.
Medical*Online
17) Ito Y, Natsume J, Kidokoro H, et al. Seizure characteristics of epilepsy in childhood after acute encephalopathy with biphasic seizures and late reduced diffusion. Epilepsia 2015 ; 56 : 1286-93.
PubMed
18) Yamanouchi H, Mizuguchi M. Acute infantile encephalopathy predominantly affecting the frontal lobes (AIEF) : a novel clinical category and its tentative diagnostic criteria. Epilepsy Res 2006 ; 70 (Suppl 1) : S263-S8.
 
19) 高梨潤一. 頭部MRI所見と病態. 小児科臨床 2012 ; 65 : 1953-8.
Medical*Online
20) Okumura A, Kidokoro H, Tsuji T, et al. Differences of clinical manifestations according to the patterns of brain lesions in acute encephalopathy with reduced diffusion in the bilateral hemispherers. AJNR Am J Neuroradiol 2009 ; 30 : 825-30.
 
21) Oguri M, Saito Y, Fukuda C, et al. Distinguishing acute encephalopathy with biphasic seizures and late reduced diffusion from prolonged febrile seizures by acute phase EEG spectrum analysis. Yonago Acta Med 2016 ; 59 : 1-14.
PubMed
22) 後藤知英. 遅発性拡散低下を呈する感染症関連急性脳症. 小児科学レクチャー 2012 ; 2 : 883-9.
 
23) Tada H, Takanashi J, Okuno H, et al. Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). J Neurol Sci 2015 ; 358 : 62-5.
PubMed
24) Yokochi T, Takeuchi T, Mukai J, et al. Prediction of acute encephalopathy with biphasic seizures and late reduced diffusion in patients with febrile status epilepticus. Brain Dev 2016 ; 38 : 217-24.
PubMed
25) Nagase H, Nakagawa T, Aoki K, et al. Therapeutic indicators of acute encephalopathy in patients with complex febrile seizures. Pediatr Int 2013 ; 55 : 310-4.
PubMed
26) 市坂有基, 小原隆史, 平井克樹, ら. 二相性脳症における早期治療介入基準についての比較検討及びその活用. 日本小児救急医学会雑誌 2018 ; 17 : 396-400.
 
27) 石田悠介, 西山将広, 徳本翔一, ら. 急性脳症の予測基準の有用性の検証 : 第1報 AESD予測のために開発された基準の別コホートにおける再検証. 脳と発達 2020 ; 52 (Suppl) : S264.
 
28) Ichiyama T, Suenaga N, Kajimoto M, et al. Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures. Brain Dev 2008 ; 30 : 47-52.
PubMed
29) Suenaga N, Ichiyama T, Kubota M, Isumi H, Tohyama J, Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproreinases 1 in acute encephalopathy following prolongaed febrile seizures. J Neurol Sci 2008 ; 266 : 126-30.
 
30) Shiihara T, Miyake T, Izumi S, et al. Serum and cerebrospinal fluid S100B, neuron-specific enolase, and total tau protein in acute encephalopathy with biphasic seizures and late reduced diffusion : a diagnostic validity. Pediatr Int 2012 ; 54 : 52-5.
PubMed
31) Tanuma N, Miyata R, Kumada S, et al. The axonal damage marker tau protein in the cerebrospinal fluid is increased in patitnes with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010 ; 32 : 435-9.
 
32) Fujii Y, Yashiro M, Yamada M, et al. Serum procalcitonin levels in acute encephalopathy with biphasic seizures and late reduced diffusion. Dis Markers 2018 ; 2018 : 2380179.
 
33) Hasegawa S, Matsushige T, Inoue H, et al. Serum and cerebrospinal fluid levels of visinin-like protein-1 in acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2014 ; 36 : 608-12.
PubMed
34) Kuya K, Fujii S, Miyoshi F, et al. A case of acute encephalopathy with biphasic seizures and late reduced diffusion : Utility of arterial spin labeling sequence. Brain Dev 2017 ; 39 : 84-8.
PubMed
35) Uetani H, Kitajima M, Sugahara T, et al. Perfusion abnormality on three-dimensional arterial spin labeling in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. J Neurol Sci 2020 ; 408 : 116558.
PubMed
36) Takanashi J, Mizuguchi M, Terai M, Barkovich AJ. Disrupted glutamate-glutamine cycle in acute encephalopathy with biphasic seizures and late reduced diffusion. Neuroradiology 2015 ; 57 : 1163-8.
PubMed
37) 水口雅. けいれん重積型 (二相性) 急性脳症のオーバービュー. 小児科臨床 2012 ; 65 : 1941-5.
Medical*Online
38) 市山高志. 病態解析と治療戦略. 脳と発達 2011 ; 43 : 118-22.
Medical*Online
39) 秋山倫之. 二相性発作と遅発性拡散能を呈する急性脳症. 小児内科 2013 ; 45 : 362-5.
 
40) 後藤知英. 急性脳症他施設研究・レジストリの経過と成果 : 関東地区から. 脳と発達 2020 ; 52 (Suppl) : S81.
 
41) Hayashi N, Okumura A, Kubota M, et al. Prognostic factors in acute encephalopathy with reduced subcortical diffusion. Brain Dev 2012 ; 34 : 632-9.
 
42) 奥村彰久. 治療 1 : ステロイドは有効か? 小児科臨床 2012 ; 65 : 1965-9.
Medical*Online
43) 池田尚広, 山形崇倫, 谷口祐子, ら. 早期ステロイドパルス療法によるけいれん重積型急性脳症発症予防効果の検討. 脳と発達 2014 ; 46 (Suppl) : S304.
 
44) Nishiyama M, Tanaka T, Fujita K, Maruyama A, Nagase H. Targeted temperature management of acute encephalopathy without AST elevation. Brain Dev 2015 ; 37 : 328-33.
PubMed
45) Murata S, Kashiwagi M, Tanabe T, et al. Targeted temperature management for acute encephalopathy in a Japanese secondary emergency medical care hospital. Brain Dev 2016 ; 38 : 317-23.
 
46) Watanabe Y, Motoi H, Oyama Y, et al. Cyclosporine for acute encephalopathy with biphasic seizures and late reduced diffusion. Pediatr Int 2014 ; 56 : 577-82.
PubMed
47) Matsuo M, Maeda T, Ono N, et al. Efficacy of dextromethorphan and cyclosporine A for acute encephalopathy. Brain Dev 2013 ; 48 : 200-5.
 
48) 石井ちぐさ, 小田新, 石川涼子, ら. けいれん重積型急性脳症への早期ビタミンB6投与経験. 日本小児救急医学会雑誌 2009 ; 8 : 35-41.
 
49) Omata T, Fujii K, Takanashi J, et al. Drugs indicated for mitochondrial dysfunction as treatments for acute encephalopathy with onset of febrile convulsive status epileptics. J Neurol Sci 2016 ; 360 : 57-60.
PubMed
50) Fukui KO, Kubota M, Terashima H, Ishiguro A, Kashii H. Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion : A case control study. Brain Dev 2019 ; 41 : 618-24.
PubMed
a) 痙攣重積型 (二相性) 急性脳症 (指定難病129). 難病情報センター. http://www.nanbyou.or.jp/entry/4515
 
b) 痙攣重積型 (二相性) 急性脳症. 小児慢性特定疾病情報センター. https://www.shouman.jp/disease/html/detail/11_32_073.html
 
c) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
P.100 掲載の参考文献
1) Sakuma H. Acute encephalitis with refractory, repetitive partial seizures. Brain Dev 2009 ; 31 : 510-4.
PubMed
2) Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS) : a peculiar form of childhood encephalitis. Acta Neurol Scand 2010 ; 121 : 251-6.
PubMed
3) van Baalen A, Hausler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES) : a nonencephalitic encephalopathy in childhood. Epilepsia 2010 ; 51 : 1323-8.
PubMed
4) Wilder-Smith EPV, Lim ECH, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome : defining a disease entity. Ann Acad Med Singap 2005 ; 34 : 417-20.
PubMed
5) Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) : State of the art and perspectives. Epilepsia 2018 ; 59 : 745-52.
PubMed
6) Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018 ; 59 : 739-44.
PubMed
7) 佐久間啓. 難治頻回部分発作重積型急性脳炎をめぐる最近の話題. 脳と発達 2013 ; 45 : 110-4.
Medical*Online
8) Farias-Moeller R, LaFrance-Corey R, Bartolini L, et al. Fueling the FIRES : Hemophagocytic lymphohistiocytosis in febrile infection-related epilepsy syndrome. Epilepsia 2018 ; 59 : 1753-63.
PubMed
9) Lee HF, Chi CS. Febrile infection-related epilepsy syndrome (FIRES) : therapeutic complications, long-term neurological and neuroimaging follow-up. Seizure 2018 ; 56 : 53-9.
PubMed
10) Lam SK, Lu WY, Weng WC, Fan PC, Lee WT. The short-term and long-term outcome of febrile infection-related epilepsy syndrome in children. Epilepsy Behav 2019 ; 95 : 117-23.
PubMed
11) Sakuma H, Tanuma N, Kuki I, Takahashi Y, Shiomi M, Hayashi M. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus. J Neurol Neurosurg Psychiatry 2015 ; 86 : 820-2.
PubMed
12) Kothur K, Bandodkar S, Wienholt L, et al. Etiology is the key determinant of neuroinflammation in epilepsy : Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus. Epilepsia 2019 ; 60 : 1678-88.
PubMed
13) Saito Y, Maegaki Y, Okamoto R, et al. Acute encephalitis with refractory, repetitive partial seizures : case reports of this unusual post-encephalitic epilepsy. Brain Dev 2007 ; 29 : 147-56.
PubMed
14) Okumura A, Komatsu M, Abe S, et al. Amplitude-integrated electroencephalography in patients with acute encephalopathy with refractory, repetitive partial seizures. Brain Dev 2011 ; 33 : 77-82.
PubMed
15) Culleton S, Talenti G, Kaliakatsos M, Pujar S,D'Arco F. The spectrum of neuroimaging findings in febrile infection-related epilepsy syndrome (FIRES) : A literature review. Epilepsia 2019 ; 60 : 585-92.
PubMed
16) Saitoh M, Kobayashi K, Ohmori I, et al. Cytokine-related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS. J Neurol Sci 2016 ; 368 : 272-6.
PubMed
17) Helbig I, Barcia G, Pendziwiat M, et al. Whole-exome and HLA sequencing in Febrile infection-related epilepsy syndrome. Ann Clin Transl Neurol 2020 ; 7 : 1429-35.
PubMed
18) Caputo D, Iorio R, Vigevano F, Fusco L. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABAAR antibodies. Eur J Paediatr Neurol 2018 ; 22 : 182-5.
PubMed
19) Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES) : pathogenesis, treatment, and outcome : a multicenter study on 77 children. Epilepsia 2011 ; 52 : 1956-65.
PubMed
20) Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010 ; 51 : 2033-7.
PubMed
21) Singh RK, Joshi SM, Potter DM, Leber SM, Carlson MD, Shellhaas RA. Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet. Pediatrics 2014 ; 134 : e1431-5.
PubMed
22) Ueda R, Saito Y, Ohno K, et al. Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. Brain Dev 2015 ; 37 : 471-7.
PubMed
23) Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases. J Child Neurol 2017 ; 32 : 35-40.
PubMed
24) Sato Y, Numata-Uematsu Y, Uematsu M, et al. Acute encephalitis with refractory, repetitive partial seizures : Pathological findings and a new therapeutic approach using tacrolimus. Brain Dev 2016 ; 38 : 772-6.
 
25) Kenney-Jung DL, Vezzani A, Kahoud RJ, et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016 ; 80 : 939-45.
PubMed
26) Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol 2018 ; 84 : 940-5.
PubMed
a) 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業) 難治頻回部分発作重積型急性脳炎の病態解明のための包括的研究 : 平成23年度～ 24年度総合研究報告書. 2013.
 

第8章 その他の急性脳症

P.107 掲載の参考文献
1) Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol 2013 ; 111 : 627-33.
PubMed
2) Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001 ; 68 : 1327-32.
PubMed
3) Miller IO, de Menezes MAS. SCN1A Seizure Disorders. In : Adam MP, Ardinger HH, Pagon RA, et al. eds. GeneReviews(R) [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-2022. 2007 Nov 29 [updated 2019 Apr 18].
 
4) Sakauchi M, Oguni H, Kato I, et al. Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 2011 ; 52 : 1144-9.
PubMed
5) Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome : search for risk factors in Japanese patients. Epilepsia 2011 ; 52 (Suppl 2) : 50-4.
 
6) Okumura A, Uematsu M, Imataka G, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia 2012 ; 53 : 79-86.
PubMed
7) Tian X, Ye J, Zeng Q, et al. The clinical outcome and neuroimaging of acute encephalopathy after status epilepticus in Dravet syndrome. Dev Med Child Neurol 2018 ; 60 : 566-73.
PubMed
8) Kobayashi K, Ouchida M, Okumura A, et al. Genetic seizure susceptibility underlying acute encephalopathies in childhood. Epilepsy Res 2010 ; 91 : 143-52.
PubMed
9) Saitoh M, Shinohara M, Hoshino H, et al. Mutations of the SCN1A gene in acute encephalopathy. Epilepsia 2012 ; 53 : 558-64.
PubMed
P.109 掲載の参考文献
1) 鞁嶋有紀, 花木啓一, 木下朋絵, 長石純一, 神崎晋. 先天性副腎過形成症の治療中にみられた中枢神経合併症 (急性脳症・痙攣重積) の全国調査. ホルモンと臨床 2002 ; 50 : 1165-9.
 
2) 李守永. 先天性副腎皮質過形成に伴う脳症. 小児内科 2013 ; 45 : 390-3.
Medical*Online
3) Abe Y, Sakai T, Okumura A, et al. Manifestations and characteristics of congenital adrenal hyperplasia-associated encephalopathy. Brain Dev 2016 ; 38 : 638-47.
PubMed
4) 阿部裕一, 山内秀雄. 先天性副腎皮質過形成に伴う脳症. 小児科学レクチャー 2012 ; 2 : 918-24.
 
5) Lee S, Sanefuji M, Watanabe K, et al. Clinical and MRI characteristic of acute encephalopathy in congenital adrenal hyperplasia. J Neurol Sci 2011 ; 306 : 91-3.
PubMed
a) 日本内分泌学会診療指針「副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針」作成委員会. 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 2015 ; 91 (Suppl) : 1-78.
 
b) 日本小児内分泌学会 (性分化・副腎疾患委員会, マススクリーニング委員会), 日本マススクリーニング学会, 日本小児泌尿器科学会, 日本内分泌学会, 厚生労働省難治性疾患政策研究事業 (副腎ホルモン産生異常に関する調査研究). 21-水酸化酵素欠損症の診断・治療のガイドライン (2021年改訂版). http://www.j-endo.jp/uploads/files/news/20211102.pdf
 
P.113 掲載の参考文献
1) Garcia-Monco JC, Cortina IE, Ferreira E, et al. Reversible splenial lesion syndrome (RESLES) : what's in a name? J Neuroimaging 2011 ; 21 : e1-e14.
 
2) 厚生労働科学研究費 (難治性疾患政策研究事業) 「良質なエビデンスに基づく急性脳症の診療確立に向けた体制整備」研究班. 平成30年度研究報告 : 急性脳症の全国実態調査 (第二回. 平成29年度実施). 2019. https://encephalopathy.jp/nsurvey_data/h29_1.pdf [閲覧日 : 2022. 11. 4]
 
3) Kasai M, Shibata A, Hoshino A, et al. Epidemiological changes of acute encephalopathy in Japan based on national surveillance for 2014-2017. Brain Dev 2020 ; 42 : 508-14.
PubMed
4) Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology 2004 ; 63 : 1854-8.
PubMed
5) Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev 2009 ; 31 : 521-8.
PubMed
6) Takanashi J, Barkovich AJ, Yamaguchi K, Kohno Y. Influenza-associated encephalitis/encephalopathy with a reversible lesion in the splenium of the corpus callosum : a case report and literature review. AJNR Am J Neuroradiol 2004 ; 25 : 798-802.
PubMed
7) Takanashi J, Barkovich AJ, Shiihara T, et al. Widening spectrum of a reversible splenial lesion with transiently reduced diffusion. AJNR Am J Neuroradiol 2006 ; 27 : 836-8.
PubMed
8) Takanashi J, Imamura A, Hayakawa F, Terada H. Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci 2010 ; 292 : 24-7.
 
9) 多田弘子, 高梨潤一. MERS. 五十嵐隆, 塩見正司, 編. 小児科臨床ピクシス 28. 急性脳炎・急性脳症. 東京 : 中山書店, 2011 : 184-7.
 
10) 多田弘子, 高梨潤一. 可逆性脳梁膨大部病変を有する軽症脳炎・脳症. 小児内科 2013 ; 45 : 366-70.
Medical*Online
11) 多田弘子, 高梨潤一. 可逆性脳梁膨大部病変を有する軽症脳炎脳症 : up-to-date. 日本小児科学会雑誌 2019 ; 123 : 814-23.
 
12) Takanashi J, Shiihara T, Hasegawa T, et al. Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination. J Neurol Sci 2015 ; 349 : 226-8.
PubMed
13) Takanashi J, Tada H, Kuroki H, Barkovich AJ. Delirious behavior in influenza is associated with a reversible splenial lesion. Brain Dev 2009 ; 31 : 423-6.
PubMed
14) Kashiwagi M, Tanabe T, Shimakawa S, et al. Clinico-radiological spectrum of reversible splenial lesions in children. Brain Dev 2014 ; 36 : 330-6.
PubMed
15) Imamura T, Takanashi J, Yasugi J, Terada H, Nishimura A. Sisters with clinically mild encephalopathy with a reversible splenial lesion (MERS) -like features ; Familial MERS? J Neurol Sci 2010 ; 290 : 153-6.
 
16) Yokoyama A, Saito Y, Kato F, Asai K, Maegaki Y, Ohno K. Transient encephalopathy with reversible white matter lesions : a case report. Brain Dev 2008 ; 30 : 434-6.
PubMed
17) Okumura A, Noda E, Ikuta T, et al. Transient encephalopathy with reversible white matter lesions in children. Neuropediatrics 2006 ; 37 : 159-62.
PubMed
18) Kurahashi H, Azuma Y, Masuda A, et al. MYRF is associated with encephalopathy with reversible myelin vacuolization. Ann Neurol 2018 ; 83 : 98-106.
PubMed
19) Takanashi J, Miyamoto T, Ando N, et al. Clinical and radiological features of rotavirus cerebellitis. AJNR Am J Neuroradiol 2010 ; 31 : 1591-5.
PubMed
20) Hatanaka M, Kashiwagi M, Tanabe T, Nakahara H, Ohta K, Tamai H. Overlapping MERS and mild AESD caused by HHV-6 infection. Brain Dev 2015 ; 37 : 334-8.
PubMed
21) Miyata R, Tanuma N, Hayashi M, et al. Oxidative stress in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Brain Dev 2012 ; 34 : 124-7.
PubMed
22) Kometani H, Kawatani M, Ohta G, et al. Marked elevation of interleukin-6 in mild encephalopathy with a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis. Brain Dev 2014 ; 36 : 551-3.
PubMed
a) 厚生労働科学研究費補助金 (新興・再興感染症研究事業) 「インフルエンザ脳症の発症因子の解明とそれに基づく発症前診断方法の確立に関する研究」班. インフルエンザ脳症ガイドライン [改訂版]. 2009. http://www.mhlw.go.jp/kinkyu/kenkou/influenza/hourei/2009/09/dl/info0925-01.pdf
 
b) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
c) 厚生労働科学研究補助金 難治性疾患克服研究事業 重症・難治性急性脳症の病因解明と診療確立に向けた研究 (研究代表者 : 水口雅) 平成22年度総括・分担研究報告書, 2011. https://mhlw-grants.niph.go.jp/system/files/2010/103071/201024105A/201024105A0001.pdf
 
P.119 掲載の参考文献
1) 赤司俊二, 城宏輔, 辻敦敏, ら. 浦和市における病原大腸菌による出血性大腸炎の臨床像. 日児誌 1991 ; 95 : 2607-15.
 
2) Magnus T, Rother J, Simova O, et al. The neurological syndrome in adults during the 2011 northern German E. coli serotype O104 : H4 outbreak. Brain 2012 ; 135 : 1850-9.
 
3) Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994 ; 125 : 511-8.
PubMed
4) 古瀬昭夫. 腸管出血性大腸菌による溶血性尿毒症症候群の中枢神経症状合併例の解析. 日児誌 2006 ; 110 : 919-25.
 
5) Sheth KJ, Swick HM, Haworth N. Neurologic involvement in hemolytic-uremic syndrome. Ann Neurol 1986 ; 19 : 90-3.
 
6) Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010 ; 5 : 1218-28.
PubMed
7) Bale JF Jr, Brasher C, Siegler RL. CNS manifestiations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis. Am J Dis Child 1980 ; 134 : 869-72.
 
8) Takanashi J, Taneichi H, Misaki T, et al. Clinical and radiological features of encephalopathy during 2011 E. coli O111 outbreak in Japan. Neurology 2014 ; 82 : 564-72.
PubMed
9) Yamada S, Shimizu M, Kuroda M, Inoue N, Sugimoto N, Yachie A. Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli. Clin Exp Nephrol 2019 ; 23 : 544-50.
 
10) Kuroda M, Shimizu M, Inoue N, et al. Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochem Int 2015 ; 85-86 : 24-30.
 
11) Theobald I, Kuwertz-Broking E, Schiborr M, Heindel W. Central nervous system involvement in hemolytic uremic syndrome (HUS) --a retrospective analysis of cerebral CT and MRI studies. Clin Nephrol 2001 ; 56 : S3-S8.
PubMed
12) Steinborn M, Leiz S, Rudisser K, Griebel M, Harder T, Hahn H. CT and MRI in haemolytic uraemic syndrome with central nervous system involvement : distribution of lesions and prognostic value of imaging findings. Pediatr Radiol 2004 ; 34 : 805-10.
PubMed
13) Donnerstag F, Ding X, Pape L, et al. Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement. Eur Radiol 2012 ; 22 : 506-13.
PubMed
14) Ishida S, Yasukawa K, Koizumi M, et al. Excitotoxicity in encephalopathy associated with STEC O-157 infection. Brain Dev 2018 ; 40 : 357-60.
PubMed
15) Dhuna A, Pascual-Leone A, Talwar D, Torres F. EEG and seizures in children with hemolytic-uremic syndrome. Epilepsia 1992 ; 33 : 482-6.
PubMed
16) Shiraishi M, Ichiyama T, Matsushige T, et al. Soluble tumor necrosis factor receptor 1 and tissue inhibitor of metalloproteinase-1 in hemolytic uremic syndrome with encephalopathy. J Neuroimmunol 2008 ; 196 : 147-52.
PubMed
17) Shimizu M, Kuroda M, Sakashita N, et al. Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine 2012 ; 60 : 694-700.
PubMed
18) Crisp DE, Siegler RL, Bale JF, Thompson JA. Hemorrhagic cerebral infarction in the hemolytic-uremic syndrome. J Pediatr 1981 ; 99 : 273-6.
PubMed
19) DiMario FJ Jr, Bronte-Stewart H, Sherbotie J, Turner ME. Lacunar infarction of the basal ganglia as a complication of hemolytic-uremic syndrome. MRI and clinical correlations. Clin Pediatr (Phila) 1987 ; 26 : 586-90.
PubMed
20) Robson WL, Leung AK, Montgomery MD. Causes of death in hemolytic uremic syndrome. Child Nephrol Urol 1991 ; 11 : 228-33.
PubMed
21) Kahn SI, Tolkan SR, Kothari O, Garella S. Spontaneous recovery of the hemolytic uremic syndrome with prolonged renal and neurological manifestations. Nephron 1982 ; 32 : 188-91.
PubMed
22) Steel BT, Murphy N, Chuang SH, McGreal D, Arbus GS. Recovery from prolonged coma in hemolytic uremic syndrome. J Pediatr 1983 ; 102 : 402-4.
 
23) Shimizu M. Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS. Pediatr Int 2020 ; 62 : 308-15.
PubMed
24) Ito M, Shiozaki A, Shimizu M, Saito S. Hemolytic-uremic syndrome with acute encephalopathy in a pregnant woman infected with epidemic enterohemorrhagic Escherichia coli : characteristic brain images and cytokine profiles. Int J Infect Dis 2015 ; 34 : 119-21.
 
25) Hosaka T, Nakamagoe K, Tamaoka A. Hemolytic uremic syndrome-associated encephalopathy successfully treated with corticosteroids. Intern Med 2017 ; 56 : 2937-41.
PubMed
26) Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998 ; 12 : 101-4.
PubMed
27) Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157 : H7 outbreak. Lancet 1999 ; 354 : 1327-30.
PubMed
28) Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark : an observational study. Lancet 2011 ; 378 : 1089-93.
PubMed
29) Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011 ; 364 : 2561-3
 
30) Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 : H4 induced haemolytic uraemic syndrome : case-control study. BMJ 2012 ; 345 : 4565.
 
31) Percheron L, Gramada R, Tellier S, et al. Eculizumab treatment in severe pediatric STEC-HUS : a multicenter retrospective study. Pediatr Nephrol 2018 ; 33 : 1385-94.
 
32) Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, et al. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab : a matched cohort study. Nephrol Dial Transplant 2020 ; 35 : 2147-53.
PubMed
33) Honda T, Ogata S, Mineo E, et al. A novel strategy for hemolytic uremic syndrome : successful treatment with thrombomodulin α. Pediatrics 2013 ; 131 : e928-33.
 
a) 溶血性尿毒症症候群の診断・治療ガイドライン作成班, 編. 溶血性尿毒症症候群の診断・治療ガイドライン. 東京 : 東京医学社, 2014.
 
b) 日本医療研究開発機構研究費 (新興・再興感染症に対する革新的医薬品等開発推進研究事業) 「新型インフルエンザ等への対応に関する研究」班. インフルエンザ脳症の診療戦略. 2018. https://www.childneuro.jp/uploads/files/about/influenzaencephalopathy2018.pdf
 
c) 厚生労働科学研究費補助金厚生労働科学特別研究事業. EHEC/O111 食中毒事例における疫学・細菌学・臨床的研究. 平成23年度総括・分担研究報告書, 2012.
 

書評

最近チェックした商品履歴

Loading...